The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

TURALIO Ⓡ (pexidartinib) is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not ...

Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor ...

Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate at week 25 of 54.0% versus 3.2% for placebo ...

Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor Wednesday, May 28, 2025 5:36PM IST ...

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

Tenosynovial Giant Cell Tumors Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that ...

Vimseltinib wins FDA approval for tenosynovial giant cell tumor, offering effective treatment with fewer side effects than previous therapies.